Preclinical results show promise for anticancer compound.

2003 JUL 1 - (NewsRx.com & NewsRx.net) -- Genta Incorporated (NASDAQ:GNTA) announced the publication of preclinical data that shows that Genasense (oblimersen sodium) enhances the effectiveness of Campath (alemtuzumab; ILEX) against both chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL) cells. The results were reported by a group from St. Bartholomew's Hospital and the Royal London School of Medicine, London, UK, and were published in the Proceedings of the Annual Meeting of the American Society of Clinical Oncology (ASCO).

Genasense inhibits production of Bcl-2, a protein that is highly expressed in malignant cells from patients with both NHL and …